Deleting an important active-site residue of diphtheria toxin, glutamic acid-148, reduces the toxin's ADPribosyltransferase activity by a factor of >104. We considered using this mutation to construct a recombinant toxoid for expression by live attenuated vaccines and explored second-site mutations that might cause reversion. Activity was partially restored by substituting glutamic acid for valine-147 or by extending the deletion by five residues toward the NH2 terminus, thereby placing glutamic acid-142 immediately adjacent to tyrosine-149. In both mutants the indicated glutamic acid may occupy a spatial locus similar to that of glutamic acid-148 in the unmutated protein. Simply deleting a crucial residue does not, therefore, provide confidence that a second-site mutation could not readily restore activity to a toxoid.
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Immunity to a bacterial toxin may be acquired naturally during the course of an infection or artificially by injection of a detoxified form of the toxin (a toxoid) (1) . Toxoids have traditionally been prepared by chemical modification of native toxins, with formaldehyde, for example (2) , but molecularly cloned toxin genes now provide alternative genetic approaches to detoxification. Besides having the potential to replace classical toxoids, recombinant toxoids could be incorporated by genetic engineering into live attenuated bacterial or viral vaccines currently being developed. Such live vaccines offer the possibility to immunize against a broad array of diseases by administering only a single dose to the vaccinee (3, 4) .
If the gene encoding a recombinant toxoid is to be included in the expression repertoire of a live vaccine, the mutation(s) that detoxifies the protein must be effectively nonrevertible while the strain remains viable within the vaccinee or in the environment. For toxins known to act as enzymes, one way to inactivate the molecule is to mutate a crucial active-site residue. Deleting such a residue might at first sight appear to be an ideal strategy, because the probability of reversion to the wild-type sequence, by insertion of an appropriate codon, should be vanishingly small. However, reversion might also occur by second-site mutations. Here we explore the effects of second-site mutations in sequences adjacent to a deletion in the active site of diphtheria toxin (DT).
EXPERIMENTAL PROCEDURES
The DT fragment A (DTA) gene was placed under control of the T7 promoter as follows. A plasmid encoding the F2 fragment of DT, pBRptacBamHIATGF2, was digested with BamHI and Cla I. The resulting 949-base-pair (bp) fragment was ligated with BamHI-and Acc I-digested M13mpl9, yielding M13mpl9-F2. An Nde I restriction site, spanning the translational start codon of F2 and a translational stop codon at Arg-192 of F2, was created by the site-directed mutagenesis procedure described (5), yielding M13mpl9-DTA. The 968-bp Nde I-HindIII fragment of M13mpl9-DTA was ligated into Nde I-and HindIII-digested pT7-7 (6), and the resulting plasmid pT7-DTA was used as a cloning vector to prepare each of the site-directed mutagenesis constructs of DTA listed in Table 1 . All site-directed mutants were constructed with M13mp19-DTA template DNA and the appropriate oligonucleotide. The 539-bp Apa I-Bal I fragment of M13mpl9-DTA, which encompassed the appropriate activesite mutation, was ligated with Apa I-and Bal I-digested pT7-DTA and used to transform competent Escherichia coli BL21-DE3 (7). Transformed clones were induced for expression, harvested by centrifugation, and fractured by freezethaw cycling, and the resulting extracts were treated with DNase I and lysozyme, clarified by centrifugation, and desalted on Sephadex G-25, as described (8) . DTA protein was then measured by Western blot analysis and ADPribosyltransferase activity was assayed, as described (9) .
RESULTS AND DISCUSSION DT belongs to a class of toxins that act by ADP-ribosylation of target proteins within sensitive cells (10, 11) . DTA (193 residues) catalyzes transfer of the ADP-ribose moiety of NAD to elongation factor 2 (10, 11), thereby inactivating the factor. This blocks protein synthesis and causes death of the cell. Glu-148 was originally identified as an active-site residue by photoaffinity labeling (12) (13) (14) . Substitution of aspartic acid, glutamine, or serine at this site diminishes enzymic and cytotoxic activities by two to three orders of magnitude, showing the exquisite dependence of activity on the spatial location and chemical nature of the Glu-148 side chain (8, 9, 14) . Deletion of a functionally similar residue in Pseudomonas aeruginosa exotoxin A, Glu-553, also causes a drastic reduction in enzymic and cytotoxic activities (15) .
Active-site deletions and substitutions were generated by oligonucleotide-directed mutagenesis of the DTA gene. The mutant genes were expressed in E. coli, and cell lysates were assayed for NAD-elongation factor 2 ADP-ribosyltransferase activity and for DT-specific protein by Western blot analysis. After deletion of Glu-148 ( with no detectable ADP-ribosylation activity. However, the next construct in this series (mutation 6), involving deletion of residues 143-148 inclusive, produced a protein with 0.6%o wild-type activity. In mutation 6, unlike mutations 1-5, the NH2-proximal residue flanking the deletion is a glutamic acid (Glu-142). Activity ranging between 0.6% and 9%o of wildtype DTA activity was observed when the NH2-proximal flanking residue of mutations 1-5 was replaced with glutamic acid creating mutations 7-11. These results are consistent with a model in which the local polypeptide on the NH2-proximal flank of Glu-148 is more flexible and less firmly anchored than the local peptide on the COOH-proximal flank. The recently determined x-ray crystallographic structure of the DT dimer provides support for this model (16) . Glu-148 resides within the antiparallel ,3-sheet bounding the active-site cleft and is only one residue removed from a large 10-residue loop (residues 137-146) that connects the Glu-148 (-strand to the adjacent NH2-proximal (-strand (Fig. 1) . Presumably, when those residues contained within this flexible loop are either deleted or replaced (Table  1 , mutations 3-6 and 8-11), the loop simply shortens in length, buffering the active site from structural distortion. The polypeptide backbone of the 4 residues immediately following Glu-148 (residues 149-152) is involved in H-bonding typical of antiparallel (3-sheet It is impossible to predict how general the phenomena here described will be among toxic proteins, but a conservative approach is clearly warranted if a modified toxin gene is to be incorporated into a live vaccine. Avoiding the incorporation of sequences encoding toxin active-site moieties altogether would be the most prudent approach. Where antibodies against epitopes on the receptor-binding moiety are known to be immunoprotective, expression of receptor-binding moieties (e.g., as subunits or fragments) alone may be sufficient and preferable. In toxins in which the enzymic moiety carries the most important neutralizing epitopes (e.g., pertussis toxin), multiple mutations, each of which independently detoxifies the molecule, are warranted. Assessment of risk ought not be made solely by focusing on the toxin alone, however, and should include consideration of other factors, including the properties of the vaccine strain itself (e.g., the extent of its multiplication in the vaccinee, its ability to persist outside the host, and its overall level of attenuation). Additional safeguards at all levels will be necessary to assure that live vaccines expressing recombinant toxoids remain innocuous and stable within the vaccinee and the environment.
